TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31982191

Group type: EXPERIMENTAL
Intervention: Diet-induced weight-loss program (calorie-restricted diet for six weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diet-induced weight-loss program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (maintained habitual diet and physical activity)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 30507829

Group type: EXPERIMENTAL
Intervention: Immersion Tub Bathing (ITB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Underrunning Water Bathing (URWB)
Number of subjects: 80
Study: 27454273

Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 5 µg of dexmedetomidine (group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5% and 0.1 mg/kg ketamine (group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg of hyperbaric bupivacaine 0.5%, 5 µg of dexmedetomidine, and 0.1 mg/kg of ketamine (group III)
Number of subjects: 90
Study: 24149919

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-help CBT
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 22688651

Group type: EXPERIMENTAL
Intervention: Rhythmic gymnasts (RG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Untrained controls (UC)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (RG and UC)
Number of subjects: 68
Study: 20088937

Group type: EXPERIMENTAL
Intervention: Avidin (100 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 18397971

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS) used daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 0
Study: 16521844

Group type: EXPERIMENTAL
Intervention: GEL (1.1 +/- 0.2 g/kg body mass carbohydrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: PLACEBO (flavored placebo drink, 426 +/- 227 mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GEL
Number of subjects: 18
Study: 14714551

Group type: EXPERIMENTAL
Intervention: Narrow band UVB
Number of subjects: 14

Group type: COMPARATOR
Intervention: Broad band UVB
Number of subjects: 14
Study: 10579151

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg orally once daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nifedipine 20 mg oral dose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rosiglitazone coadministration
Number of subjects: 28
Study: 8610720

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microgram) + metaproterenol sulfate (15 mg)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Metaproterenol sulfate (15 mg)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide + metaproterenol sulfate
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 213
Study: 1742892

Group type: EXPERIMENTAL
Intervention: Aspiration of middle ear effusions prior to ventilation tube insertion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ears with effusion aspirated
Number of subjects: 50
Study: 6279223

Group type: EXPERIMENTAL
Intervention: Chromic catgut
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Polypropylene
Number of subjects: 231
Study: 2998440

Group type: EXPERIMENTAL
Intervention: Bread with 10 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bread with 16 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bread with 30 g bran (raw or baked) and fermentation times of 15 min, 45 min, 3 h, or 16 h
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bread with no bran, but phytate and Zn added equivalent to 10 g bran
Number of subjects: 42
Study: 29223712

Group type: EXPERIMENTAL
Intervention: 2700K light exposure (55lx)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 6500K light exposure (55lx)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both 2700K and 6500K light exposure
Number of subjects: 16
Study: 26481981

Group type: EXPERIMENTAL
Intervention: Optic nerve sheath diameter assessment via ultrasonography
Number of subjects: 13
Study: 23452436

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab with last acuity of drop-outs carried forward
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab in late phase
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab in early phase
Number of subjects: 312
Study: 22295830

Group type: EXPERIMENTAL
Intervention: General anesthesia with Han's acupoint nerve stimulator (HANS) for 30 min, bilateral Zusanli (ST 36) and Sanyinjiao (SP 6)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: General anesthesia with Han's acupoint nerve stimulator (HANS) for 30 min, bilateral Hegu (LI 4) and Taichong (LR 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only general anesthesia
Number of subjects: 90
Study: 20103782

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) - 6 mg/m² every 4 weeks for 3 cycles
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group - no postremission therapy
Number of subjects: 232
Study: 18051017

Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control
Number of subjects: 81
Study: 16191743

Group type: EXPERIMENTAL
Intervention: D2 dopamine receptor TaqI A polymorphism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11945097

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 800 mg/day
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 10556609

Group type: EXPERIMENTAL
Intervention: Attend-auditory group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attend-visual group
Number of subjects: 0
Study: 8609329

Group type: EXPERIMENTAL
Intervention: Defibrillation shocks equal to the upper limit of vulnerability (11.3 +/- 4.6 J)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Defibrillation shocks at upper limit of vulnerability plus 3 J (14.3 +/- 4.6 J)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Defibrillation test shocks at upper limit of vulnerability
Number of subjects: 40
Study: 1888345

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (stimulus control/relaxation training)
Number of subjects: 30
Study: 6405771

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 0
Study: 31412032

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable anaesthesia
Number of subjects: 0
Study: 30400939

Group type: EXPERIMENTAL
Intervention: Weekly high-dose recombinant human erythropoietin (EPO) 40,000 IU/mL for 12 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (saline) infusions for 12 weeks
Number of subjects: 104
Study: 26790543

Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total space closure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 100
Study: 24715364

Group type: EXPERIMENTAL
Intervention: Clozapine plasma levels (Clz pl≥300μg/L)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clozapine plasma levels (Clz pl<300μg/L)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clozapine plasma levels
Number of subjects: 19
Study: 22713233

Group type: EXPERIMENTAL
Intervention: Bodyblade Pro
Number of subjects: 11

Group type: COMPARATOR
Intervention: 10-lb dumbbell
Number of subjects: 11
Study: 20843911

Group type: EXPERIMENTAL
Intervention: Duloxetine 60‐120 mg/day
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 17585670

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus acupuncture at Shenshu (BIL 23), Mingmen (GV 4), Yaoyangguan (GV 3), and Weizhong (BL 40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acupuncture at Shenshu (BIL 23), Mingmen (GV 4), Yaoyangguan (GV 3), and Weizhong (BL 40)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus acupuncture
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 78
Study: 15793941

Group type: EXPERIMENTAL
Intervention: Pneumococcal seven-valent conjugate vaccine (Prevenar)
Number of subjects: 115
Study: 12400812

Group type: EXPERIMENTAL
Intervention: Direct primary stenting (group 1, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endoscopic atraumatic coronary artery bypass grafting (group 2, n = 50)
Number of subjects: 100
Study: 11607795

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg or Enalapril 20 mg (for patients ≤40 years); Amlodipine 10 mg + Atenolol 50 mg or Enalapril 20 mg + Hydrochlorothiazide 25 mg (for patients >40 years)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Amlodipine-based regimen
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Enalapril-based regimen
Number of subjects: 1106
Study: 9893735

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg twice a day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: L-NMMA (0.75, 1.5, and 3.0 mg/kg/h)
Number of subjects: 10
Study: 8281874

Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg four times a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 2604918

Group type: EXPERIMENTAL
Intervention: 2% carbon monoxide exposure
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4% carbon monoxide exposure
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (air without added carbon monoxide)
Number of subjects: 63
Study: 1089439

Group type: EXPERIMENTAL
Intervention: Fegan's method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operation
Number of subjects: 0
Study: 7223302

Group type: EXPERIMENTAL
Intervention: Albumin therapy (60-75 g postoperatively)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no albumin)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59

Group type: COMPARATOR
Intervention: Albumin therapy and Control
Number of subjects: 59
Study: 31647931

Group type: EXPERIMENTAL
Intervention: Interventional trials
Number of subjects: 390
Study: 30185291

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention (e.g., medication dose adjustment, initiation, or discontinuation)
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Factors predictive of requiring an intervention (e.g., clopidogrel dispensing, fall, vertebral fracture diagnosis)
Number of subjects: 2594

Group type: EXPERIMENTAL
Intervention: Validation of the predictive model
Number of subjects: 2594
Study: 27038924

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 110
Study: 24355669

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Workstations-only intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison group (usual practice)
Number of subjects: 44
Study: 22313514

Group type: EXPERIMENTAL
Intervention: Remi-Pro-Rocu group (n = 62)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Pro-Rocu-Remi group (n = 64)
Number of subjects: 126
Study: 20602433

Group type: EXPERIMENTAL
Intervention: School-based group CBT
Number of subjects: 148

Group type: COMPARATOR
Intervention: Structured after-school activity group
Number of subjects: 148
Study: 17660026

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1 g twice daily for 12 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyclophosphamide, 1.5 mg/kg/d for 12 months
Number of subjects: 64
Study: 16043178

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nifedipin
Number of subjects: 80
Study: 11799102

Group type: EXPERIMENTAL
Intervention: Aliskiren 40 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aliskiren 80 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aliskiren 160 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Enalapril 20 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10320183

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream (EMLA; Astra, Sweden) for 1 hour postburn
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream for 1 hour postburn
Number of subjects: 10
Study: 8542174

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for colorectal cancer
Number of subjects: 0
Study: 1961137

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg midazolam HCl
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7144067

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 16
Study: 31958286

Group type: EXPERIMENTAL
Intervention: First-line EGFR inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31073879

Group type: EXPERIMENTAL
Intervention: Group-Based Cognitive Behavioral Therapy (CBT), 12 sessions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 71
Study: 30096070

Group type: EXPERIMENTAL
Intervention: TDF/FTC (tenofovir/emtricitabine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27101402

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ICECAP-O
Number of subjects: 71
Study: 23640540

Group type: EXPERIMENTAL
Intervention: mTBI
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: no diagnosis
Number of subjects: 108

Group type: COMPARATOR
Intervention: concussion
Number of subjects: 108
Study: 22231680

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners, including training and consultations for patients.
Number of subjects: 490

Group type: COMPARATOR
Intervention: Usual care by general practitioners (control group).
Number of subjects: 490
Study: 20573086

Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 12
Study: 17535463

Group type: EXPERIMENTAL
Intervention: Spatial strategy during free-choice phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incentive to perform as well as possible
Number of subjects: 0

Group type: COMPARATOR
Intervention: Difficulty executing the better alternative (cancellation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prone to making errors at the spatial strategy
Number of subjects: 0
Study: 16266457

Group type: COMPARATOR
Intervention: 500 micromol/L Hcy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Folic acid with 500 micromol/L Hcy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hcy in AMI group
Number of subjects: 101
Study: 12202284

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (E-EPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10428146

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg once daily for 12 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice daily for 12 months
Number of subjects: 46
Study: 7785475

Group type: EXPERIMENTAL
Intervention: Women in their first year on campus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both women and men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study: 2097149

Group type: EXPERIMENTAL
Intervention: CAP (C = 600 mg/sqm, A = 45 mg/sqm, P = 50 mg/sqm)
Number of subjects: 134

Group type: COMPARATOR
Intervention: CA (C = 600 mg/sqm, A = 45 mg/sqm)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: CAP
Number of subjects: 134

Group type: COMPARATOR
Intervention: CA
Number of subjects: 134
Study: 381127

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cimetidine group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 42
Study: 31797578

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Filgotinib 450 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52
Study: 30001701

Group type: EXPERIMENTAL
Intervention: CHIP-Family intervention (includes a one-day workshop for parents and children, psychological exercises based on the Fun FRIENDS protocol, sports exercises, and a follow-up session 4 weeks later)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (no psychosocial intervention)
Number of subjects: 0
Study: 27538157

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Common equipment (dental elevators, chisels, forceps)
Number of subjects: 40
Study: 24936902

Group type: EXPERIMENTAL
Intervention: Progressive-overload whole-body vibration training (WBV)
Number of subjects: 18
Study: 22700666

Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 110
Study: 20368673

Group type: EXPERIMENTAL
Intervention: Standard wound care with > or = 50% percent area reduction (PAR) at week 4
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Standard wound care with < 50% percent area reduction (PAR) at week 4
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard wound care regardless of baseline size category
Number of subjects: 142
Study: 18578875

Group type: EXPERIMENTAL
Intervention: Behavioral counseling intervention (10 sessions)
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Behavioral counseling intervention
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1044
Study: 16041547

Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg daily (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily (n=6)
Number of subjects: 12
Study: 12366605

Group type: EXPERIMENTAL
Intervention: Shared care programme (SCP)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 875
Study: 10375366

Group type: EXPERIMENTAL
Intervention: BCG vaccination at 34-35 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: BCG vaccination at 38-40 weeks
Number of subjects: 62
Study: 7748680

Group type: EXPERIMENTAL
Intervention: BiliBlanket phototherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 44
Study: 2405456

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (SD) restricted to the 2 hours between 3:00 and 5:00 in the morning
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (SD)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No sleep deprivation (undisturbed sleep)
Number of subjects: 33
Study: 6778197

Group type: COMPARATOR
Intervention: Diltiazem 120 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diltiazem 240 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 13
Study: 31809409

Group type: EXPERIMENTAL
Intervention: ExDEF (exercise energy deficit)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ExBAL (exercise energy balance)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ExDEF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ExBAL
Number of subjects: 15

Group type: COMPARATOR
Intervention: NoEx (nonexercise control)
Number of subjects: 15
Study: 31815653

Group type: EXPERIMENTAL
Intervention: Short course systemic antibiotics (≤ 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long course systemic antibiotics (≥ 4 weeks)
Number of subjects: 0
Study: 27864471

Group type: EXPERIMENTAL
Intervention: Lunch Is in the Bag intervention
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 633
Study: 25315169

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pubovaginal sling (PVS)
Number of subjects: 40
Study: 23575759

Group type: EXPERIMENTAL
Intervention: Blake drain (silastic tube), removed on postoperative day (POD) 5
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional mediastinal tube, removed on POD 1
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blake drain (silastic tube)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional mediastinal tube
Number of subjects: 150
Study: 21616989

Group type: EXPERIMENTAL
Intervention: Sound-field amplification (SFA) devices
Number of subjects: 147

Group type: COMPARATOR
Intervention: No sound-field amplification (SFA) devices
Number of subjects: 147
Study: 18804218

Group type: EXPERIMENTAL
Intervention: Bayesian adaptive design
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: COMPARATOR
Intervention: Active control with known side effect
Number of subjects: 156
Study: 16505865

Group type: EXPERIMENTAL
Intervention: Course in coping with depression
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 15523542

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 21

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 21
Study: 11259887

Group type: EXPERIMENTAL
Intervention: Guedel-type airway
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 30